DEF 14A: Viridian Therapeutics Seeks Stockholder Approval for Director Elections, Auditor Ratification, Executive Compensation, and Equity Incentive Plan Amendment

Viridian Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 17, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

Summary

• Viridian Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 17, 2024, at 3:00 p.m. Eastern Time.
• Stockholders will vote on the election of two Class III director nominees, ratification of KPMG LLP as the independent auditor, an advisory vote on executive compensation, and approval of an amendment to the 2016 Equity Incentive Plan.
• The proposed amendment to the 2016 Equity Incentive Plan includes an increase of 2,000,000 shares available for issuance.
• The Board of Directors recommends voting FOR the director nominees and FOR Proposals 2, 3, and 4.
• The record date for determining stockholders eligible to vote is April 23, 2024.
• The company has retained Innisfree M&A Incorporated to assist in soliciting proxies for a fee of up to $50,000, plus expenses.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are typical for a public company, and the Board's recommendations are clearly stated. The sentiment is slightly positive due to the company's efforts to engage with stockholders and address their concerns.

Positives

• The proposed amendment to the 2016 Equity Incentive Plan is intended to align employee interests with those of stockholders and to attract and retain talented service providers.
• The Board actively seeks to achieve a diversity of occupational and personal backgrounds on the Board.
• The company has adopted a formal process by which stockholders may communicate with the Board or any of its directors.
• The company has adopted an incentive compensation clawback policy.

Negatives

• The company's three-year average burn rate through December 31, 2023, relating to the Existing 2016 Plan, was approximately 13.8%.
• The company's overhang relating to the 2008 Plan, the Existing 2016 Plan, the 2020 Plan and the Inducement Awards as of March 31, 2024, was 16%.
• If the Amended 2016 Plan is approved, the company's overhang would increase to approximately 18%.

Risks

• The Proxy Statement contains forward-looking statements that are subject to substantial risks and uncertainties.
• Failure to ratify the selection of KPMG as the company's independent auditor will require the committee to reconsider its selection.
• If the Amended 2016 Plan is not approved, the company's ability to provide retention incentives to executives and other employees will be limited.

Future Outlook

The company expects the number of additional shares being requested for approval will be sufficient to meet its expected needs for approximately one year based on historical grant practices and performance.

Management Comments

• Stephen Mahoney, President and Chief Executive Officer: 'Whether or not you expect to participate in the virtual Annual Meeting, please vote as promptly as possible in order to ensure your representation at the Annual Meeting.'

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, and executive compensation disclosures.

Comparison to Industry Standards

• The executive compensation practices, including base salary, bonus, and equity incentives, are typical for biotechnology companies of similar size and stage of development.
• The use of a compensation consultant (Radford) to benchmark executive compensation against peer companies is a common practice.
• The corporate governance structure, including an independent board chairman and various committees, aligns with best practices for publicly traded companies.
• The equity incentive plan and its proposed amendment are consistent with industry standards for attracting and retaining talent in the competitive biotechnology sector.

Management Changes

Corporate Governance

Related Party Transactions

• In January 2022, we and Paragon Therapeutics, Inc. (Paragon) entered into an antibody and discovery option agreement (the Paragon Agreement) under which we and Paragon will cooperate to develop one or more proteins or antibodies.
• In October 2020, Viridian Therapeutics, Inc. (a private company prior to its acquisition by us on October 27, 2020 pursuant to an agreement and plan of merger, Private Viridian) entered a license agreement with Zenas BioPharma (Cayman) Limited (Zenas BioPharma) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma.
• On October 30, 2023, we entered into a Securities Purchase Agreement (the Securities Purchase Agreement) for a private placement (the Private Placement) with certain institutional and accredited investors (collectively, the Purchasers).
• In April 2021, we entered into a sublease with Cogent Biosciences, Inc. (Cogent), which was subsequently amended.

Stakeholder Impact

• Approval of the equity incentive plan amendment will impact employees, directors, and consultants by providing them with a proprietary interest in the company.
• The advisory vote on executive compensation allows stockholders to express their views on the company's compensation policies.
• The election of directors will impact the overall governance and strategic direction of the company, affecting all stakeholders.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting, which is important for investors and creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals before the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting.
• Final voting results will be published in a Current Report on Form 8-K to be filed with the SEC within four business days after the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, director election, executive compensation, equity incentive plan, KPMG, auditor ratification, corporate governance, Viridian Therapeutics